aTYR PHARMA INC
ATYR · XNASCIK 1339970fmd_0Q465XK2ARCQ6E7F9ZKPTG6W49Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2013 to Sep 30, 2026, 52 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 0 | 10 | 0 | 10 | 0 | 0 | 0 |
| Research and development | 43 | 30 | 20 | 14 | 17 | 23 | 43 | 42 | 54 | 60 |
| Total operating expenses | 58 | 47 | 33 | 23 | 26 | 34 | 57 | 55 | 68 | 78 |
| Operating income | (58) | (47) | (33) | (23) | (16) | (34) | (46) | (55) | (68) | (78) |
| Other non-operating income (expense) | 0 | (1) | (2) | (1) | (0) | 0 | 1 | 5 | 4 | 4 |
| Income before taxes | (58) | (48) | (35) | (24) | (16) | (34) | (45) | (50) | (64) | (74) |
| Income tax expense | (0) | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (58) | – | (35) | (24) | (16) | (34) | (45) | (50) | (64) | (74) |
| Net income | (58) | (48) | (35) | (16) | (16) | (34) | (45) | (50) | (64) | (74) |
| Net income to common shareholders | (58) | (48) | – | – | – | – | – | – | – | – |